Anavex Presents 31-Week Efficacy Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients at AAIC 2016
Go back to Anavex Presents 31-Week Efficacy Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients at AAIC 2016| Anavex Life Sciences Corp. (NASDAQ: AVXL) | Delayed: 2.69 -0.02 (0.74%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.71 | 52 Week High | $8.30 | |||
| Open | $2.67 | 52 Week Low | $2.43 | |||
| Day High | $2.79 | P/E | N/A | |||
| Day Low | $2.66 | EPS | $-0.22 | |||
| Volume | 370,605 | |||||
